Loading…
INmune Bio Inc. is projected to rise to $2.77 by 2027, a +50% move from its current price of $1.85. INMB is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.78 | $1.85 | $1.93 | +0.07% |
| Aug 6 | $1.75 | $1.85 | $1.97 | +0.15% |
| Aug 7 | $1.73 | $1.85 | $1.99 | +0.23% |
| Aug 8 | $1.71 | $1.86 | $2.02 | +0.30% |
| Aug 9 | $1.69 | $1.86 | $2.04 | +0.38% |
| Aug 10 | $1.68 | $1.86 | $2.06 | +0.45% |
| Aug 11 | $1.67 | $1.86 | $2.08 | +0.53% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.67 | $1.86 | $2.08 | +0.53% |
| Week 2 | $1.60 | $1.87 | $2.18 | +1.05% |
| Week 3 | $1.55 | $1.88 | $2.27 | +1.59% |
| Week 4 | $1.52 | $1.89 | $2.35 | +2.12% |
| Week 5 | $1.48 | $1.90 | $2.43 | +2.66% |
| Week 6 | $1.46 | $1.91 | $2.50 | +3.20% |
| Week 7 | $1.43 | $1.92 | $2.57 | +3.74% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
INmune Bio Inc. is a clinical-stage immunology company focused on developing drugs to reprogram the patients innate immune system to treat disease in the United States. The company aims to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Its development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome, and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. The company has license agreements with Xencor, Immune Ventures, LLC; GOSH; and University of Pittsburg.
The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.
INmune Bio Inc. (INMB) is a healthcare company currently trading at $1.72 with a market cap of $45.73M and a rank of 4491. The stock is positioned within a volatile space given its clinical-stage focus and early-stage programs.
ForecasteD numbers show a path from a neutral near term to stronger long‑term upside, with the 2026 average at $1.72 and a multi-year rise culminating in a 2050 average of $17.42 and a 912.9% ROI. This implies meaningful upside potential over the extended horizon while reflecting considerable uncertainty inherent to developmental therapies.
A major floor 45.8% below — a decisive break under it would weaken the trend.
The nearest floor, 27.0% below — buyers have tended to step in here.
The nearest ceiling, 11.9% above — a clean break opens room to run.
A major ceiling 32.1% above — clearing it would confirm fresh momentum.
Key INMB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of INMB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.73 | Buy | $1.74 | Buy |
| MA 10 | $1.78 | Buy | $1.77 | Buy |
| MA 20 | $1.83 | Buy | $1.76 | Buy |
| MA 50 | $1.57 | Buy | $1.64 | Buy |
| MA 100 | $1.46 | Buy | $1.59 | Buy |
| MA 200 | $1.54 | Buy | $1.96 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.34 | Neutral |
| Stoch RSI (14) | 21.80 | Neutral |
| CCI (20) | -43.26 | Neutral |
| Williams %R (14) | -71.11 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -15.46 | Sell |
| Bollinger %B (20,2) | 0.36 | Neutral |
| Stochastic %K (14) | 28.89 | Neutral |
| TRIX (15) | 0.74 | Buy |
| Awesome (5,34) | 0.06 | Buy |
| Ultimate (7,14,28) | 44.18 | Neutral |
| Momentum (10) | -0.15 | Sell |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 1.72 | Buy |
| ADX (14) | 17.62 | Neutral |
| ATR (14) | 0.07 | Info |
The 30-day technical picture shows a bullish overall sentiment but with near-term balance. RSI 14 is 50, and the stock trades around the SMA50 of $1.54 and the SMA200 of $1.55, indicating a tight range near long‑standing averages.
The 30-day price range runs from a low of $1.28 to a high of $2.31, with a defined support at $1.21 and resistance at $2.07. Annualized volatility is high at 90%, underscoring substantial price swings despite the neutral-to-bullish setup.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.12 | $1.85 | $2.83 | 0% | Neutral | |
| $2.11 | $2.77 | $3.92 | +50% | Bullish | |
| $2.23 | $3.08 | $4.58 | +66% | Bullish | |
| $2.61 | $3.73 | $5.78 | +102% | Bullish | |
| $2.49 | $3.68 | $5.91 | +99% | Bullish | |
| $2.38 | $3.64 | $6.02 | +97% | Bullish | |
| $2.66 | $4.19 | $7.11 | +126% | Bullish | |
| $2.81 | $4.55 | $7.91 | +146% | Bullish | |
| $3.78 | $6.28 | $11.15 | +240% | Bullish | |
| $4.24 | $7.23 | $13.10 | +291% | Bullish | |
| $4.69 | $9.05 | $17.79 | +389% | Bullish | |
| $9.33 | $20.73 | $45.75 | +10.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.12 | $1.85 | $2.41 | +0.00% |
| September 2026 | $1.66 | $2.00 | $2.49 | +7.97% |
| October 2026 | $1.63 | $1.98 | $2.50 | -0.83% |
| November 2026 | $1.71 | $2.10 | $2.69 | +5.87% |
| December 2026 | $1.77 | $2.19 | $2.83 | +4.26% |
Click any year to see its month-by-month INMB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect INMB to range from $1.12 to $2.83 through 2026. The $1.85 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The INMB price prediction for 2027 points to an average of $2.77 (low $2.11, high $3.92) — a potential gain of +50% on today's $1.85. Momentum favours further upside here.
In 2028, INMB is projected to trade between $2.23 and $4.58, averaging $3.08 — a potential gain of +66% from today's $1.85. That is up +11% on the projected 2027 average. Buyers look set to stay in control over this stretch.
INmune Bio Inc.'s 2029 outlook centres on $3.73, within a $2.61 to $5.78 range. That is up +21% on the projected 2028 average. That marks a +102% change versus current levels. Momentum favours further upside here.
By 2030, INMB could reach as high as $5.91, with a base case around $3.68 and support toward $2.49 — roughly +99% from $1.85. Buyers look set to stay in control over this stretch.
Expect INMB to range from $2.38 to $6.02 through 2031. The $3.64 average target implies a +97% move from current prices. That is -1% versus the projected 2030 average. Momentum favours further upside here.
The INMB price prediction for 2032 points to an average of $4.19 (low $2.66, high $7.11) — a potential gain of +126% on today's $1.85. Buyers look set to stay in control over this stretch.
In 2033, INMB is projected to trade between $2.81 and $7.91, averaging $4.55 — a potential gain of +146% from today's $1.85. That is up +9% on the projected 2032 average. Momentum favours further upside here.
INmune Bio Inc.'s 2034 outlook centres on $6.28, within a $3.78 to $11.15 range. That is up +38% on the projected 2033 average. That marks a +240% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, INMB could reach as high as $13.10, with a base case around $7.23 and support toward $4.24 — roughly +291% from $1.85. Momentum favours further upside here.
Expect INMB to range from $4.69 to $17.79 through 2040. The $9.05 average target implies a +389% move from current prices. That is up +25% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The INMB price prediction for 2050 points to an average of $20.73 (low $9.33, high $45.75) — a potential gain of +10.2x on today's $1.85. Momentum favours further upside here.
Investing $1,000 in INMB today (≈ 540.540541 INMB) could be worth
$11,203.07
+$10,203.07 (+1020%) by 2050 · US Dollar
Based on the average projected INMB price of $20.73 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in INMBwould be worth at today's price.
$1,000 invested in INMB on Jul 31, 2025 (≈ 366.300364 INMB) would be worth
$677.66
-$322.34 (-32.2%) today · 0.68× · US Dollar
Based on a INMB entry price of $2.73 vs. today's $1.85.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.62 | $1,141.98 | +14.2% |
| 1 month ago | $1.68 | $1,101.19 | +10.1% |
| 3 months ago | $1.51 | $1,225.17 | +22.5% |
| 6 months ago | $1.58 | $1,170.89 | +17.1% |
| 1 year ago | $2.73 | $677.66 | -32.2% |
| All time (5.0y) ago | $14.95 | $123.75 | -87.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our INMB forecast.
Our base-case forecast reaches $3.70 around 2029.
Implied market cap at $3.70: $98.37M
The multi-year forecast shows a path of rising averages and solid upside potential. In 2027 the average is projected at $2.57 with a 49.2% ROI and bullish sentiment, followed by 2028 at $2.91 (68.9% ROI) and 2029 at $3.42 (98.7% ROI). By 2030 the average is $3.33 with a 93.5% ROI and bullish sentiment, and the growth continues toward 2040 with an average of $7.95 and a 361.9% ROI.
The model projects a 2050 average price of $17.42 with a 912.9% ROI and bullish sentiment, highlighting sizable long‑term upside while acknowledging the inherent uncertainty and non-guaranteed nature of these estimates.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $3.33, with a low of $2.20 and a high of $5.46, and a projected ROI of 93.5% with bullish sentiment.
The forecast turns bullish from 2027 onward, with the average price rising to $17.42 by 2050 and a projected ROI of 912.9%. The 2026 estimate is $1.72 (neutral), indicating potential but not guaranteed upside over the longer term.
Yes. The 2033 forecast shows an average of $4.01 with a min of $2.40 and a max of $7.15, indicating it can exceed $4 on the way to the long‑term target.
The 30-day range is $1.28 to $2.31.
Current price is $1.72 and market cap is $45.73M.
INmune Bio Inc. Community Discussion
0Share your INmune Bio Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.